Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Department of Obstetrics and Gynecology, Akita University Graduate School of Medicine School of Medicine, Akita, Japan.
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003827.
Dendritic cells (DCs) play critical roles in regulating the innate and adaptive immune responses, and have long been a major focus of cancer immunotherapy. Accumulating evidence suggests that conventional type 1 DCs (cDC1s) excel in cross-presentation of exogenous antigens on MHC-I molecules and induction of antitumor CD8 T cell immunity; however, obtaining large numbers of cDC1s is difficult. The use of reprogramming and differentiation technology is advantageous for obtaining unlimited numbers of autologous cDC1s especially for therapeutic interventions where repeated vaccinations are required. However, generation of cDC1s from human induced pluripotent stem cells (iPSCs) remains elusive.
Human iPSCs established from peripheral blood T cells and monocytes were differentiated to myeloid cells under on-feeder or feeder-free culture conditions in vitro. Phenotype, genomic and transcriptomic signature, and function of human iPSC-derived DCs were analyzed. The role of Notch signaling for the generation of HLA-DR cells from human iPSCs was interrogated by a loss- and gain-of-function approach.
Flow cytometric analyses and single-cell profiling of HLA-DR cells revealed that human iPSCs gave rise to CD141XCR1CLEC9A cells (cDC1s), CLEC4ACLEC10ACD1c cells (cDC2As), CLEC4ACLEC10ACD1c cells (cDC2Bs), CD163CD5CD1c cells (CD5cDC2s), and AXLSIGLEC6 cells (AS-DCs) on OP9 feeder cells expressing the Notch ligand delta-like 1 (OP9-DL1) while the majority of iPSC-derived cells differentiated on OP9 cells were CD163CD5CD1c cells (DC3s) and monocytes. Plasmacytoid DCs were not differentiated from iPSCs on either OP9 or OP9-DL1 cells. Inhibition of Notch signaling during co-culture of iPSC-derived CD34 hematopoietic progenitor cells with OP9-DL1 cells abrogated generation of cDC1s, cDC2As, cDC2Bs, CD5cDC2s, and AS-DCs but increased frequency of DC3s. Notch-activated human iPSC-derived XCR1CLEC9AHLA-DRCD11c cells exhibited similar gene expression profile with peripheral blood cDC1s. Human iPSC-derived DCs have phagocytic, T-cell proliferative, and cytokine-producing functions.
Our study demonstrates a critical role of Notch signaling in regulating developmental pathway of human cDCs. These findings provide insights into the future development of personalized treatment with unlimited numbers of autologous cDCs from human iPSCs.
树突状细胞(DCs)在调节先天和适应性免疫反应中发挥着关键作用,一直是癌症免疫治疗的主要焦点。越来越多的证据表明,传统的 1 型树突状细胞(cDC1)擅长在 MHC-I 分子上交叉呈递外源性抗原,并诱导抗肿瘤 CD8 T 细胞免疫;然而,获得大量 cDC1 是困难的。使用重编程和分化技术有利于获得大量自体 cDC1,特别是在需要重复接种疫苗的治疗干预中。然而,从人诱导多能干细胞(iPSCs)中生成 cDC1 仍然难以实现。
从外周血 T 细胞和单核细胞中建立的人 iPSCs 在体外的饲养细胞或无饲养细胞条件下分化为髓样细胞。分析人 iPSC 衍生的 DC 的表型、基因组和转录组特征和功能。通过失活和功能获得方法探究 Notch 信号在人 iPSC 生成 HLA-DR 细胞中的作用。
流式细胞术分析和 HLA-DR 细胞的单细胞分析表明,人 iPSCs 产生 CD141XCR1CLEC9A 细胞(cDC1)、CLEC4ACLEC10ACD1c 细胞(cDC2As)、CLEC4ACLEC10ACD1c 细胞(cDC2Bs)、CD163CD5CD1c 细胞(CD5cDC2s)和 AXLSIGLEC6 细胞(AS-DCs),而在表达 Notch 配体 delta-like 1(OP9-DL1)的 OP9 饲养细胞上分化的大多数 iPSC 衍生细胞为 CD163CD5CD1c 细胞(DC3s)和单核细胞。iPSCs 既不能在 OP9 细胞上也不能在 OP9-DL1 细胞上分化为浆细胞样树突状细胞。在 iPSC 衍生的 CD34 造血祖细胞与 OP9-DL1 细胞共培养过程中抑制 Notch 信号,会破坏 cDC1、cDC2As、cDC2Bs、CD5cDC2s 和 AS-DCs 的生成,但增加了 DC3s 的频率。Notch 激活的人 iPSC 衍生的 XCR1CLEC9AHLA-DRCD11c 细胞与外周血 cDC1 具有相似的基因表达谱。人 iPSC 衍生的 DC 具有吞噬、T 细胞增殖和细胞因子产生功能。
本研究表明 Notch 信号在调节人 cDC 发育途径中起着关键作用。这些发现为未来开发使用人 iPSC 产生大量自体 cDC 的个性化治疗提供了思路。